Transdel Pharmaceuticals Enters Into License Agreement with JH Direct, LLC for Cosmeceutical...

Transdel Pharmaceuticals Enters Into License Agreement with JH Direct, LLC for
Cosmeceutical Product

Agreement Includes Exclusive Worldwide License to Transdel's Anti-Cellulite
Cosmeceutical Product

LA JOLLA, Calif., June 10 /PRNewswire-FirstCall/ -- Transdel Pharmaceuticals,
Inc. (OTC Bulletin Board: TDLP) and JH Direct, LLC have entered into a
licensing agreement providing JH Direct with the exclusive worldwide rights to
Transdel's anti-cellulite cosmeceutical product which utilizes Transdel's
patented transdermal delivery system technology, Transdel(TM). The licensing
agreement between Transdel and JH Direct is a significant milestone for
Transdel as it is the first agreement involving the use of Transdel's
proprietary technology for a cosmeceutical product. Transdel plans to further
develop its pipeline of cosmetic/cosmeceutical products.

Under the terms of the agreement, JH Direct will pay Transdel initial royalty
advances and a continuing licensing royalty on the worldwide sales of the
anti-cellulite product. The product will be launched through direct response
television campaigns, created and managed by JH Direct, followed by an
expansion into traditional channels of distribution, such as retail or
wholesale channels. Transdel has retained the exclusive rights to seek
pharmaceutical/dermatological partners for the anti-cellulite product for an
initial period of one year, thereafter JH Direct will be allowed to expand in
this channel.

"We are extremely pleased with our relationship with JH Direct and plan on
building on this relationship to launch additional cosmeceutical products.
This venture is very exciting as we believe it could represent the beginning
of what may become a revenue stream for Transdel. An estimated 85% to 90% of
women develop cellulite following puberty. The size of this target market
combined with the desire to remove cellulite represents a $3 billion market
and thus provides a promising market opportunity," stated Dr. Juliet Singh,
President and Chief Executive Officer of Transdel. "We also plan on expanding
our pipeline to include formulations for anti-aging, varicose vein and
hyperpigmentation cosmetic/cosmeceutical products."

"We feel that the anti-cellulite product provides a significant market
opportunity for JH Direct. The use of Transdel's propriety transdermal
delivery system in the product will make it unique and potentially more
effective than other products currently on the market," said Johann Verheem,
JH Direct's Chief Executive Officer. "We anticipate bringing this product to
market rapidly and expanding our relationship with Transdel in other areas."

About Transdel Pharmaceuticals, Inc.

Transdel Pharmaceuticals, Inc. (OTCBB: TDLP) is a specialty pharmaceutical
company developing non-invasive, topically delivered products. The Company's
innovative-patented Transdel(TM) cream formulation technology is designed to
facilitate the effective penetration of a variety of products through the
tough skin barrier. The Company is actively investigating other product
candidates for transdermal delivery using the Transdel(TM) platform technology
and is also actively pursuing partnerships with other groups or companies to
expand its product portfolio.

The Company's lead pain product, Ketotransdel(R), a topical cream based
non-steroidal anti-inflammatory drug ("NSAID"), is currently in Phase 3
clinical studies in the United States. Ketotransdel, if approved by the U.S.
Food and Drug Administration, could become the first topical NSAID cream
product in the United States for acute pain management, which is a
multi-billion dollar market. The drug could address what the Company believes
is a significant unmet medical need for patients and physicians seeking a
potentially safer alternative to existing pain management approaches, such as
oral NSAIDs. The Company anticipates reporting top-line results from this
study during the third quarter of 2009. For more information, please visit
http://www.transdelpharma.com.

About JH Direct, LLC

JH Direct LLC is a fully integrated Direct Response Television Company
focusing on developing sustainable brands launched through direct response
television campaigns as part of a multi-channel distribution approach. The JH
Direct senior management team has created and managed some of the most
successful Direct Response Television brands in the cosmeceutical, beauty and
fitness categories since the mid nineties.

JH Direct is funded by JH Partners, a San Francisco-based private equity firm
focused on building sustainable, long-term equity value in consumer and
marketing-driven growth companies. www.jhpartners.com

Safe Harbor Statement

Statements made in this release that are not historical in nature constitute
forward-looking statements. Forward-looking statements can be identified by
the use of words such as "expects," "plans," "will," "may," "anticipates,"
"believes," "should," "intends," "estimates," and other words of similar
meaning. Please note that forward-looking statements are based on
projections, that these projections involve judgment, and that individual
judgments may vary. Moreover, these statements are subject to risks and
uncertainties that cannot be predicted or quantified and consequently, actual
results may differ materially from those expressed or implied by such
forward-looking statements. Such risks and uncertainties include, without
limitation, risks and uncertainties associated with the uncertainty of the
Company's future financial results and its ability to raise additional funds
to support its operations, its ability to complete the required clinical
trials and obtain FDA approval for Ketotransdel, the efficacy and the
commercial success of any cosmetic/cosmeceutical products it develops, the
impact of competitive products or pricing, and technological changes. More
detailed information about the Company and the risk factors that may affect
the realization of forward-looking statements is set forth in the Company's
filings with the Securities and Exchange Commission, including its Annual
Report on Form 10-K and its Quarterly Reports on Form 10-Q filed with the SEC.
Such documents may be read free of charge on the SEC's web site at
www.sec.gov. All forward-looking statements included in this release are made
as of the date of this press release, and the Company assumes no obligation to
update any such forward-looking statements.

SOURCE Transdel Pharmaceuticals, Inc.

John Lomoro, CFO, Transdel Pharmaceuticals, Inc., +1-858-457-5300,
johnl@transdelpharma.com; Sharon Haughey, Director of Marketing, JH Direct,
LLC, Sharon@jhdirect.net